295 related articles for article (PubMed ID: 24367792)
1. The real-life effectiveness of palivizumab for reducing hospital admissions for respiratory syncytial virus in infants residing in Nunavut.
Banerji A; Panzov V; Young M; Lee BE; Mamdani M; Giles BL; Dennis M; Morel J; Bisson D; Paes BA; Hui C; Mahony J
Can Respir J; 2014; 21(3):185-9. PubMed ID: 24367792
[TBL] [Abstract][Full Text] [Related]
2. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
Romero JR
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
[TBL] [Abstract][Full Text] [Related]
3. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
[TBL] [Abstract][Full Text] [Related]
4. Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization.
Buckley BC; Roylance D; Mitchell MP; Patel SM; Cannon HE; Dunn JD
J Manag Care Pharm; 2010; 16(1):15-22. PubMed ID: 20044843
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the cost of hospitalization for respiratory syncytial virus disease versus palivizumab prophylaxis in Canadian Inuit infants.
Banerji A; Lanctôt KL; Paes BA; Masoud ST; Tam DY; Macdonald WA; Roberts A
Pediatr Infect Dis J; 2009 Aug; 28(8):702-6. PubMed ID: 19461555
[TBL] [Abstract][Full Text] [Related]
6. Palivizumab for the prevention of respiratory syncytial virus infection.
Rogovik AL; Carleton B; Solimano A; Goldman RD
Can Fam Physician; 2010 Aug; 56(8):769-72. PubMed ID: 20705882
[TBL] [Abstract][Full Text] [Related]
7. Partial palivizumab prophylaxis and increased risk of hospitalization due to respiratory syncytial virus in a Medicaid population: a retrospective cohort analysis.
Krilov LR; Masaquel AS; Weiner LB; Smith DM; Wade SW; Mahadevia PJ
BMC Pediatr; 2014 Oct; 14():261. PubMed ID: 25308481
[TBL] [Abstract][Full Text] [Related]
8. Prevention of respiratory syncytial virus infection with palivizumab.
Thomas M; Bedford-Russell A; Sharland M
Monaldi Arch Chest Dis; 2000 Aug; 55(4):333-8. PubMed ID: 11057088
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants.
Joffe S; Ray GT; Escobar GJ; Black SB; Lieu TA
Pediatrics; 1999 Sep; 104(3 Pt 1):419-27. PubMed ID: 10469764
[TBL] [Abstract][Full Text] [Related]
10. Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016-2017 epidemic season: a systematic review of seven Italian reports.
Cutrera R; Wolfler A; Picone S; Rossi GA; Gualberti G; Merolla R; Del Vecchio A; Villani A; Midulla F; Dotta A
Ital J Pediatr; 2019 Nov; 45(1):139. PubMed ID: 31706338
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany.
Roeckl-Wiedmann I; Liese JG; Grill E; Fischer B; Carr D; Belohradsky BH
Eur J Pediatr; 2003 Apr; 162(4):237-44. PubMed ID: 12647196
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of Palivizumab Against Respiratory Syncytial Virus Hospitalization Among Preterm Infants in a Setting With Year-Round Circulation.
Yeo KT; Yung CF; Khoo PC; Saffari SE; Sng JSP; How MS; Quek BH
J Infect Dis; 2021 Jul; 224(2):279-287. PubMed ID: 33274362
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and Safety of Palivizumab for the Prevention of Serious Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus: A Systematic Review.
Gonzales T; Bergamasco A; Cristarella T; Goyer C; Wojdyla M; Oladapo A; Sawicky J; Yee J; Moride Y
Am J Perinatol; 2024 May; 41(S 01):e1107-e1115. PubMed ID: 36452969
[TBL] [Abstract][Full Text] [Related]
14. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.
Frogel MP; Stewart DL; Hoopes M; Fernandes AW; Mahadevia PJ
J Manag Care Pharm; 2010; 16(1):46-58. PubMed ID: 20131495
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.
Andabaka T; Nickerson JW; Rojas-Reyes MX; Rueda JD; Bacic Vrca V; Barsic B
Cochrane Database Syst Rev; 2013 Apr; (4):CD006602. PubMed ID: 23633336
[TBL] [Abstract][Full Text] [Related]
16. The cost effectiveness of palivizumab in term Inuit infants in the Eastern Canadian Arctic.
Tam DY; Banerji A; Paes BA; Hui C; Tarride JE; Lanctôt KL
J Med Econ; 2009; 12(4):361-70. PubMed ID: 19900071
[TBL] [Abstract][Full Text] [Related]
17. Respiratory-related hospitalizations following prophylaxis in the Canadian registry for palivizumab (2005-2012) compared to other international registries.
Paes B; Mitchell I; Li A; Harimoto T; Lanctôt KL
Clin Dev Immunol; 2013; 2013():917068. PubMed ID: 23861694
[TBL] [Abstract][Full Text] [Related]
18. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
;
Pediatrics; 2014 Aug; 134(2):e620-38. PubMed ID: 25070304
[TBL] [Abstract][Full Text] [Related]
19. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
;
Pediatrics; 2014 Aug; 134(2):415-20. PubMed ID: 25070315
[TBL] [Abstract][Full Text] [Related]
20. Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations.
Paes B; Mitchell I; Li A; Lanctôt KL
Eur J Pediatr; 2012 May; 171(5):833-41. PubMed ID: 22203430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
